Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Cash & Current Investments (2020 - 2025)

Historic Cash & Current Investments for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to $25.6 million.

  • Ovid Therapeutics' Cash & Current Investments fell 5917.37% to $25.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.6 million, marking a year-over-year decrease of 5917.37%. This contributed to the annual value of $53.1 million for FY2024, which is 4985.07% down from last year.
  • Ovid Therapeutics' Cash & Current Investments amounted to $25.6 million in Q3 2025, which was down 5917.37% from $38.3 million recorded in Q2 2025.
  • Over the past 5 years, Ovid Therapeutics' Cash & Current Investments peaked at $233.1 million during Q1 2021, and registered a low of $25.6 million during Q3 2025.
  • In the last 5 years, Ovid Therapeutics' Cash & Current Investments had a median value of $105.8 million in 2023 and averaged $116.8 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first soared by 41437.56% in 2021, then crashed by 5917.37% in 2025.
  • Quarter analysis of 5 years shows Ovid Therapeutics' Cash & Current Investments stood at $187.8 million in 2021, then tumbled by 31.31% to $129.0 million in 2022, then fell by 17.96% to $105.8 million in 2023, then tumbled by 49.85% to $53.1 million in 2024, then crashed by 51.76% to $25.6 million in 2025.
  • Its last three reported values are $25.6 million in Q3 2025, $38.3 million for Q2 2025, and $43.0 million during Q1 2025.